Company news

Voyager Therapeutics, Inc. news in 2025

Voyager Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Voyager Reports Third Quarter 2025 Financial and Operating Results

November 10, 2025

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

November 10, 2025

Voyager Reports Second Quarter 2025 Financial and Operating Results

August 6, 2025

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

July 16, 2025

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 10, 2025

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

May 15, 2025

Voyager Reports First Quarter 2025 Financial and Operating Results

May 6, 2025

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

April 28, 2025

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

March 31, 2025

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

March 11, 2025

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

March 4, 2025

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

March 3, 2025

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

February 25, 2025

Voyager Provides Update on SOD1 ALS Gene Therapy Program

February 10, 2025

Calls in 2025

Decks in 2025